Triple

T16851986
Position Surface form Disambiguated ID Type / Status
Subject Biktarvy E409696 entity
Predicate developedBy P73 FINISHED
Object Gilead Sciences E84182 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Gilead Sciences | Statement: [Biktarvy, developedBy, Gilead Sciences]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Gilead Sciences
Context triple: [Biktarvy, developedBy, Gilead Sciences]
  • A. Gilead Sciences (board member) chosen
    Gilead Sciences is a major American biopharmaceutical company known for developing antiviral drugs, including treatments for HIV, hepatitis C, and other serious diseases.
  • B. Amgen
    Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
  • C. Regeneron Pharmaceuticals
    Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
  • D. Biogen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • E. BioMarin Pharmaceutical
    BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d88395e6c88190b22730f335107c14 completed April 10, 2026, 4:59 a.m.
NER Named-entity recognition batch_69e3b379b8fc81908d8bc9950c7f8bad completed April 18, 2026, 4:38 p.m.
NED1 Entity disambiguation (via context triple) batch_6a012ec9611c8190a773beef59b39110 completed May 11, 2026, 1:20 a.m.
Created at: April 10, 2026, 5:24 a.m.